DS 8201

Drug Profile

DS 8201

Alternative Names: DS-8201a; DS8201

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer
  • Phase I Solid tumours

Most Recent Events

  • 11 Oct 2017 Daiichi Sankyo, Japan Agency for Medical Research and Development and National Cancer Center plan a phase II trial for Uterine carcinosarcoma (Metastatic disease, Recurrent, Second-line therapy or greater) in Japan (IV) (UMIN000029506)
  • 09 Oct 2017 Daiichi plans a phase II trial for Gastric cancer (Late-stage disease) in Japan and South Korea (JapicCTI-173727)
  • 01 Oct 2017 Phase-II clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea, Japan (IV) (JapicCTI-173727)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top